Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Atazanavir/Cobicistat Fixed-Dose Combination in Healthy Adults
NCT04263350Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atazanavir and cobicistat in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of Atazanavir, Maximum observed plasma concentration of Cobicistat and 2 more. Started Feb 2020; status: completed.
02
Drugs
atazanavircobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04263350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263350.